Idexx Laboratories opened higher at $583.75, compared with its previous close of $575.98. In the last trading session, the stock traded between $560.82 and $586.00. It showed a downward intraday trend.
return calculator
Time Period
An investment of $100 made 5 years ago in Idexx Laboratories is now worth
$ 84.30
resulting in a loss of
$ 15.70 (15.70%)
invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 10 Analysts
Buy
60%
Hold
40%
Sell
0%
Markets Today
Today's Change
$-14.45 (-2.51%)
Day High
$586.00
Day Low
$560.82
Day Open
$583.75
Prev Close
$575.98
Volume
2,65,449
1W Return
-0.91%
1M Return
5.22%
3M Return
-1.44%
6M Return
1.42%
1Y Return
-10.54%
Fundamentals
Market Cap ($ Mn)
44,238
PE Ratio
39.00
PB Ratio
27.25
PEG Ratio
3.50
ROE
69.35%
ROCE
63.28%
EPS (TTM)
$4.29
Investment Returns
1 Week
-0.91%
1 Month
5.22%
3 Months
-1.44%
6 Months
1.42%
9 Months
-17.02%
Financials
Quarterly
All values in $ Mn
954.3
Dec 24
998.4
Mar 25
1.1K
Jun 25
1.1K
Sep 25
1.1K
Dec 25
1.2K
Jun 26
Updates
16Oct
JP Morgan lowers IDEXX Labs price target to $750, keeps overweight
JP Morgan maintains an Overweight rating on IDEXX Laboratories. Price target lowered from $775 to $750 by analyst Chris Schott. Rating status remains unchanged despite the reduction in target price.
14 days ago
1Oct
IDEXX Laboratories to release Q3FY26 results on November 2, 2026
IDEXX Laboratories schedules Q3FY26 results release for November 2, 2026. Analyst conference call set for 8:30 am ET on the same day. Webcast and earnings snapshot available via IDEXX investor relations website.
29 days ago
17Sep
IDEXX expands Faecal Dx in UK with taeniid tapeworm detection
IDEXX adds taeniid tapeworm detection to Faecal Dx platform in UK. Covers Taenia and Echinococcus species, aligning with ESCCAP guidelines. More than 50 million Faecal Dx tests run globally since 2012 launch. Positive tapeworm results trigger complimentary Echinococcus RealPCR test. Detection now includes seven major intestinal parasite groups.
1mo ago
31Aug
IDEXX Labs to hold fireside chat at Morgan Stanley healthcare conference
Mike Erickson and Andrew Emerson to lead fireside chat. Session scheduled for September 14, 2026, at Morgan Stanley conference. Live audio webcast available on IDEXX investor relations page. Company serves customers in more than 175 countries.
1mo ago
4Aug
IDXX Laboratories Q2 Results: EPS rises 17.63% YoY to $4.27
IDXX Laboratories exceeded Q2 expectations with EPS of $4.27 (+17.63% YoY) and sales of $1.217 billion (+9.69% YoY). The earnings beat of 7.83% over estimates signals strong operational leverage and margin expansion, outpacing the modest 1.36% sales beat.
2mo ago
4Aug
IDXX Laboratories raises FY26 EPS guidance, narrows sales outlook
IDXX Laboratories upgraded its FY2026 GAAP EPS guidance to $14.69-$14.94, beating the $14.67 estimate, and narrowed sales outlook to $4.700B-$4.745B from $4.675B-$4.760B. The changes reflect stronger profitability expectations and increased visibility into revenue performance.
